These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 28089633)

  • 41. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution.
    Rosenthal R; McGranahan N; Herrero J; Taylor BS; Swanton C
    Genome Biol; 2016 Feb; 17():31. PubMed ID: 26899170
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular pathways in the development and treatment of oesophageal cancer.
    Walker RC; Underwood TJ
    Best Pract Res Clin Gastroenterol; 2018; 36-37():9-15. PubMed ID: 30551862
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Histopathological landscape of rare oesophageal neoplasms.
    Businello G; Dal Pozzo CA; Sbaraglia M; Mastracci L; Milione M; Saragoni L; Grillo F; Parente P; Remo A; Bellan E; Cappellesso R; Pennelli G; Michelotto M; Fassan M
    World J Gastroenterol; 2020 Jul; 26(27):3865-3888. PubMed ID: 32774063
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Study of MicroRNA expression profiles of esophageal cancer.
    Mishima T; Akagi I; Miyashita M; Ishibashi O; Mizuguchi Y; Tajiri T; Takizawa T
    J Nippon Med Sch; 2009 Feb; 76(1):43. PubMed ID: 19305112
    [No Abstract]   [Full Text] [Related]  

  • 45. Serial real-time monitoring of circulating tumour cells and cell-free DNA in blood for prognosis of oesophageal carcinoma: abridged secondary publication.
    Lung ML
    Hong Kong Med J; 2023 Feb; 29 Suppl 2(1):4-7. PubMed ID: 36950996
    [No Abstract]   [Full Text] [Related]  

  • 46. Molecular classification of lung cancer: a cross-platform comparison of gene expression data sets.
    Parmigiani G; Garrett E; Anbazhagan R; Gabrielson E
    Chest; 2004 May; 125(5 Suppl):103S. PubMed ID: 15136439
    [No Abstract]   [Full Text] [Related]  

  • 47. Tumor genomics vs. tumor genetics: a paradigm shift?
    Meltzer SJ
    Gastroenterology; 2001 Sep; 121(3):726-9. PubMed ID: 11522757
    [No Abstract]   [Full Text] [Related]  

  • 48. Predicting cancer: can we? Should we?
    Coburn C
    Lancet Oncol; 2016 Nov; 17(11):1494. PubMed ID: 27819231
    [No Abstract]   [Full Text] [Related]  

  • 49. Expanding the Lauren classification: a new gastric cancer subtype?
    Turner ES; Turner JR
    Gastroenterology; 2013 Sep; 145(3):505-8. PubMed ID: 23891604
    [No Abstract]   [Full Text] [Related]  

  • 50. Germline Determinants of Esophageal Adenocarcinoma.
    Lee M; Eng G; Handte-Reinecker A; ; Deshpande VS; Yilmaz OH; Gala MK
    Gastroenterology; 2023 Nov; 165(5):1276-1279.e7. PubMed ID: 37507074
    [No Abstract]   [Full Text] [Related]  

  • 51. Genetic Defect in Submucosal Gland-Associated Caveolin-3: A New Paradigm in Esophageal Adenocarcinoma Risk.
    Garman KS; Purkayastha BPD; Hogue JA; Fecteau R; ; Guda K; Chak A
    Gastroenterology; 2023 Dec; 165(6):1561-1564.e3. PubMed ID: 37659676
    [No Abstract]   [Full Text] [Related]  

  • 52. Familial aggregation of esophageal cancer.
    Li S; Hopper JL
    Chin Med J (Engl); 2023 Nov; 136(21):2644-2646. PubMed ID: 37925596
    [No Abstract]   [Full Text] [Related]  

  • 53. Treatment of oesophageal cancer - Stressing the patient perspective.
    Lordick F
    Eur J Cancer; 2017 Oct; 84():360-362. PubMed ID: 28942866
    [No Abstract]   [Full Text] [Related]  

  • 54. A decade of the Oesophageal Cancer Clinical and Molecular Stratification Consortium.
    Peters CJ; Ang Y; Ciccarelli FD; Coles H; Coleman HG; Contino G; Crosby T; Devonshire G; Eldridge M; Freeman A; Grehan N; McCord M; Nutzinger B; Zamani S; Parsons SL; Petty R; Sharrocks AD; Skipworth RJE; Smyth EC; Soomro I; Underwood TJ; ; Fitzgerald RC
    Nat Med; 2024 Jan; 30(1):14-16. PubMed ID: 38114667
    [No Abstract]   [Full Text] [Related]  

  • 55. Molecular and genetic markers in thoracic surgery.
    Petersen RP; D'Amico TA
    Ann Thorac Surg; 2006 Dec; 82(6):2335-6. PubMed ID: 17131544
    [No Abstract]   [Full Text] [Related]  

  • 56. Does microbiota composition act as predictive signature for the evaluation of chemoimmunotherapy response efficacy?
    Martinelli S; Lamminpää I; Amedei A
    J Gastrointest Oncol; 2024 Feb; 15(1):529-532. PubMed ID: 38482237
    [No Abstract]   [Full Text] [Related]  

  • 57. Causal association between dietary factors and esophageal diseases: A Mendelian randomization study.
    Zou M; Liang Q; Zhang W; Zhu Y; Xu Y
    PLoS One; 2023; 18(11):e0292113. PubMed ID: 38019753
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sulforaphene suppresses oesophageal cancer growth through mitogen- and stress-activated kinase 2 in a PDX mouse model.
    Zhang C; Wu Q; Yao K; Jin G; Zhao S; Zhang J; Zheng W; Xu B; Zu Y; Yuan J; Liu K; Guo Y
    Am J Cancer Res; 2023; 13(10):4708-4720. PubMed ID: 37970356
    [TBL] [Abstract][Full Text] [Related]  

  • 59. circPOLR1C Promotes the Development of Esophageal Cancer by Adsorbing miR-361-3p and Regulating Cancer Cell Apoptosis and Metastasis.
    Fang Y; Yin J; Shen Y; Wang H; Tang H; Chen X
    J Oncol; 2022; 2022():9124142. PubMed ID: 36590309
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: A network meta-analysis.
    Fan N; Wang Z; Zhou C; Bludau M; Contino G; Zhao Y; Bruns C
    EClinicalMedicine; 2021 Dec; 42():101183. PubMed ID: 34805809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.